IND submission is a major milestone in the life of your drug. We can provide all supporting analytical data to help ensure a smooth application process.
We have the expertise, flexibility, and resources to provide a full range of pharmaceutical API custom development services at every stage of the lifecycle.
We can provide lab-, kilo- and pilot-scale manufacturing for preclinical studies and all phases of clinical trials, supplying milligram to kilogram quantities.
Cambrex brings more than 40 years of generic API manufacturing experience to its pharmaceutical partners. From our sites in Italy, Sweden, and the USA, we are a leading global supplier of generic APIs.
Drug substance tech transfer sounds so simple on the surface, but it’s a complex activity carrying a number of technical, regulatory, and quality risks.
At Snapdragon Chemistry, now part of Cambrex, our chemists specialize in creating custom solutions and technologies to take on your toughest process development and production challenges. This includes expertise in designing and building reactors that enable seamless technology transfer as a process scales up for commercial manufacturing.
At Cambrex, we provide a range of technologies equipped to solve your API manufacturing challenges, and we are flexible enough to handle the most complex molecules.
If you’re looking to outsource drug product development to a CDMO, you need a collaborative partner who will engage you deeply to understand the unique needs of your project.
From pre-formulation to commercial manufacturing and packaging, you can trust Cambrex to deliver your complex dosage forms with the perfect combination of technology, expertise, and collaboration.
We are equipped to take on projects at any size or scale, offering established pediatric formulation and development expertise and to-scale manufacturing capabilities.
Biopharma companies at all stages of development, rely on our expertise and broad capabilities to produce the clinical trial supply of drug products they need, when they need them.
You can rely on our extensive portfolio of analytical development solutions and testing services to rapidly advance your molecule for the greatest chance of success.
Cambrex offers a comprehensive suite of testing services for complex biopharmaceuticals including standalone analytical R&D, method validation, release testing, ICH stability, and routine QC testing.
We’re solid state chemistry experts who can deliver timely, phase-appropriate solutions to optimize the physical stability of your API, develop a more bioavailable formulation or overcome other challenges.
Cambrex’s experienced analysts are well-equipped to ensure microbial testing is of the highest quality for our customers and delivered with a quick and reliable turnaround.
Cambrex and Q1 Scientific’s stability storage and sample management capabilities provide a variety of pharmaceutical storage conditions, with walk-in and reach-in chambers that meet all ICH Q1A requirements.
Cambrex is here to support you in early-phase development. Our development experts apply their ingenuity and skill to address your unique challenges.
Our teams of creative problem-solvers work closely with you to accelerate drug development timelines, optimize processes, and meet regulatory requirements.
We understand that the commercial phase of drug development can be challenging, especially when it comes to manufacturing at scale and meeting changing market demands.
Cambrex is a leading global supplier of more than 70 generic APIs, as well as intermediates and derivatives.
Pharmaceutical companies of all sizes are often challenged to identify a CDMO partner that can truly grow with their candidates in early development. An organization may kick off drug development with one proposed indication and smaller production volumes in mind but, as clinical results emerge and indications are added, additional API demands may begin to outstrip their partner’s capacity.
For drug developers commercializing orphan drugs, the search to find small-scale commercial partners presents another unique challenge. Over the past two years, the FDA has approved more orphan drugs than non-orphan drugs, often with fast-track status. To meet this need, CDMOs must be able to scale quickly within their facilities to help their clients progress therapies from early clinical toward validation and commercial launch.
Cambrex recently invested $30 million in the expansion of its API development and small-scale commercial capabilities in High Point, North Carolina. On this webinar, Brian Swierenga, VP of Operations and Site Director, High Point and Dan Bowles, Senior Director of Chemical Development, High Point, discuss how their facility and the Cambrex network are evolving to enhance capabilities and accelerate API development.
Thank you for your interest in our content.
In this article, Cambrex’s Chief Scientific Officer and President of Snapdragon Chemistry, Matthew Bio, sat down with CPHI for an interview to talk about the project that won Snapdragon the 2023 CPHI Pharma Award for API Development.
Process validation is a key step in preparing for commercial active pharmaceutical ingredient (API) production, requiring a significant depth of knowledge and data related to the manufacturing process. Read our whitepaper to learn how Cambrex applied process improvement methodology to the process validation step in order to reduce costs for our client.
As more novel therapies and orphan drugs fill the drug development pipeline, small-scale CDMO capabilities have become an increasingly common need for sponsors developing and commercializing new drug entities.